Why Is DaVita (DVA) Stock Down -14.91% Today?
Key Takeaways
- DaVita shares plunged 14.91% to $194.00 in intraday trading, following a sharp post-earnings sell-off that began in Tuesday's after-hours session.
- The primary catalyst was a disappointing full-year guidance outlook despite Q2 results beating analyst expectations on both revenue and earnings.
- Concerns over declining revenue per treatment, commercial insurance mix deterioration, and rising cost pressures outweighed the headline earnings beat.
- Profit-taking likely amplified the move after the stock had surged roughly 100% year-to-date and touched an all-time high of $247.49 just two sessions earlier.
- Broader market sentiment was mixed, with the S&P 500 down modestly, though DVA's decline was almost entirely company-specific.
- Traders are now watching for analyst revisions, any Medicare regulatory updates, and whether the sell-off stabilizes near key technical support levels.
Opening Summary
DVA, the stock of Denver-based kidney dialysis giant DaVita Inc., cratered 14.91% to $194.00 during Wednesday's trading session, erasing billions in market value. The previous session's close stood at $227.99. The rout was triggered by the company's second-quarter earnings report, released after Tuesday's closing bell. While DaVita beat Wall Street's estimates for both revenue and adjusted earnings per share, investors zeroed in on the company's decision to reaffirm — rather than raise — its full-year profit guidance, along with several forward-looking headwinds around cost inflation and payer mix.
Q2 Earnings Beat Overshadowed by Guidance and Margin Concerns
DaVita reported Q2 revenue of $3.55 billion, a 5.2% year-over-year increase that topped the $3.50 billion consensus estimate. Adjusted earnings per share came in at $4.02, comfortably ahead of the $3.88 Wall Street had projected. Adjusted operating income reached $579 million, and free cash flow totaled $256 million. Treatment volume growth accelerated 56 basis points year-over-year, supported by lower-than-expected patient mortality — a genuinely encouraging operational signal.
Yet the stock sold off sharply because management reiterated its full-year 2026 adjusted EPS guidance of $14.65 at the midpoint — a figure that landed below the analyst consensus of approximately $14.85. For a stock that had rallied roughly 100% year-to-date and was trading near all-time highs, the market was clearly positioned for an upward guidance revision. When none materialized, a wave of selling ensued.
Revenue Per Treatment and Commercial Mix Pressure
The earnings call surfaced several structural headwinds that deepened investor unease. Revenue per treatment declined sequentially by about $2 from the first quarter, reflecting lower phosphate-binder revenue and a weakening commercial insurance mix tied to the expiration of Affordable Care Act subsidies. CFO Joel Ackerman guided that revenue-per-treatment growth in the second half of 2026 would turn slightly negative on a year-over-year basis.
The commercial mix deterioration is particularly significant: DaVita flagged a $40 million headwind in 2026 from the shift of patients away from higher-reimbursing commercial plans, with that figure rising to an estimated $70 million in 2027. These payer-mix dynamics directly pressure profitability in DaVita's core U.S. dialysis business.
Cost Inflation and G&A Growth Add to the Bear Case
On the expense side, patient care costs per treatment grew more than 3% year-to-date, running above the company's full-year target range. General and administrative expenses rose 10% year-over-year in the quarter, contributing to margin compression. While DaVita expects cost growth to moderate in the second half, the first-half trajectory rattled investors who had priced in improving operating leverage from accelerating treatment volumes.
Market Context and Trading Activity
The sell-off in DVA was far more severe than the broader market's modest decline. The S&P 500 was down roughly 0.3% on Wednesday, and the healthcare sector showed no comparable weakness, confirming the move was overwhelmingly company-specific. Trading volume was dramatically elevated: Tuesday's regular session already saw over 2.6 million shares change hands versus a typical daily average of roughly 800,000 to 940,000, and Wednesday's intraday activity continued at an accelerated pace.
From a technical standpoint, DVA had hit a 52-week high of $247.49 on August 3, and the stock was meaningfully extended above its 50-day and 200-day moving averages. The vertical nature of the year-to-date rally — shares had approximately doubled from their 52-week low of $101.00 — left the stock acutely vulnerable to profit-taking on any hint of disappointment. Wednesday's plunge sliced through several near-term support levels in a single session.
Analyst Reaction
Barclays raised its price target on DaVita from $218 to $224 following the earnings report while maintaining an "Equal Weight" rating — signaling that even a mildly constructive revision was not enough to alter the cautious stance. The broader analyst consensus remains a "Hold," with an average price target of approximately $217.50. With the stock trading well below that level intraday, some analysts may view the sell-off as overdone, but the immediate post-earnings reaction underscores how elevated expectations had become.
What Comes Next for DVA
The near-term focus will be on whether the sell-off stabilizes or triggers further technical selling. Key upcoming catalysts include the Centers for Medicare & Medicaid Services' final 2027 ESRD prospective payment system rule, which could materially affect dialysis reimbursement rates. DaVita is also advancing its expanded hemodialysis (expanded HD) deployment, a clinical initiative that could improve patient outcomes but is not expected to generate a meaningful financial benefit until at least 2028.
Additionally, the company's ongoing share buyback program — which included 2.2 million shares repurchased in Q2 — may provide some downside support if management accelerates repurchases at lower prices. However, risks remain elevated: commercial mix pressures are expected to intensify through 2027, cost inflation is not fully tamed, and the regulatory environment for dialysis providers remains in flux.
Trending AI Robots
For investors seeking to navigate volatile market conditions with data-driven strategies, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of automated trading bots covering thousands of tickers across various strategies, timeframes, and performance metrics, but only the strongest performers under current market conditions are featured in this dynamically updated section. Whether you favor momentum, value, or pattern-recognition approaches, exploring the Trending AI Robots page can help you identify systematic strategies aligned with today's market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
DVA's RSI Indicator ascends from oversold territory
The RSI Oscillator for DVA moved out of oversold territory on August 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 20 of the 28 cases the stock moved higher. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for DVA just turned positive on August 26, 2026. Looking at past instances where DVA's MACD turned positive, the stock continued to rise in 26 of 42 cases over the following month. The odds of a continued upward trend are 62%.
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where DVA advanced for three days, in 237 of 349 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
DVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 132 of 237 cases where DVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DVA as a result. In 50 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 7 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. DVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (91.743) is normal, around the industry mean (208.196). P/E Ratio (15.125) is within average values for comparable stocks, (175.365). Projected Growth (PEG Ratio) (0.437) is also within normal values, averaging (2.496). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.968) is also within normal values, averaging (2.688).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of integrated dialysis services for patients suffering from chronic kidney failure
Industry HospitalNursingManagement
Advertisement